K. Mdluli

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

The paper evaluates contezolid as a potential replacement for linezolid in combination with bedaquiline and pretomanid in a murine tuberculosis model, finding comparable activity and no cross-resistance.

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model

This study evaluates new tuberculosis treatments in mice, finding that replacing bedaquiline with TBAJ-587 reduces relapse, while replacing linezolid with TBI-223 has no significant effect.

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

This study compares the efficacy of TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse tuberculosis model, finding TBAJ-587 more effective and less prone to resistance.

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.